Sector News

Young startups on new-look Hong Kong exchange see major CEO pay packets

September 2, 2019
Life sciences

We’re all used to seeing Big Pharma CEOs take home the biggest pay packets, but after a relaxing of listing rules in Hong Kong, we’re seeing some very early-stage biotechs handing out some major and even comparable checks to their leaders.

Last year, Ken Frazier, CEO and chair of Big Pharma Merck, a consistent top 10 revenue earner across all pharmas, got a very healthy $20.9 million in total compensation. That’s a huge wage but one you’d expect from a CEO leading one of pharma’s, and indeed the world’s, biggest companies, raking in nearly $43 billion in sales a year.

So, you might expect that the CEO of a much, much smaller startup, which isn’t even making money yet, to make a fraction of that.

Not so: We learned from data compiled by S&P Global Market Intelligence out this week that the total reported compensation of Jiang Ningjun, the CEO of CStone Pharmaceuticals, was a staggering 141.25 million yuan (just under $20 million) last year, putting him on par with Frazier.

But then, CStone has been impressive with its funding drive: Back in 2016, it got off a major $150 million series A round, and last year it was in the top 10 biggest funding rounds for all biotechs, taking in a $260 million series B.

Back in February, the biotech picked up another HK$2.1 billion ($266 million) when it went public on the Hong Kong Stock Exchange, which relaxed its rules for early-stage, prerevenue biotechs in 2018 and has allowed us to see CEOs’ pay packets.

And it’s not just CStone: The paychecks of all the CEOs on the Hong Kong list more than doubled last year, according to its report, with many not too far off from what U.S. pharma CEOs can expect.

Alexander Krasavin, partner and chief commercial officer for human capital solutions for the Asia Pacific and Middle East regions at consultancy Aon, told S&P that this shouldn’t be too much of a shock given that Chinese biotech companies “tend to use remuneration paid to U.S. executives in the sector as a benchmark to decide on what they pay their own executives.”

He added: “CEOs of precommercial biotech companies globally are compensated based on the future value of the company that they are expected to deliver through their leadership.

“Whether or not the executive’s compensation is sustainable is determined by how confident the company’s shareholders and board of directors are of the executive’s ability to deliver that value.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.